Cytoreduction/HIPEC surgery for peritoneal mesothelioma involves two distinct parts: surgery and heated chemotherapy. Both are essential to completely debulking the abdominal cavity of tumors.
Both are integral to extending survival by precious weeks, months or even years for patients.
A new report in the American Journal of Translational Research explains how HIPEC, the heated chemotherapy part, improves the surgery as a whole. HIPEC stands for heated intraperitoneal chemotherapy.
The analysis included 44 patients with malignant peritoneal mesothelioma. The report focused on overall survival and inpatient recovery time, among other aspects.
All of the cases underwent cytoreductive surgery. This procedure often removes the omentum, peritoneal lining, and possibly other organs like the spleen. The idea of cytoreductive surgery is to take out the bulky tumors and any visible microscopic tumors.
In some cases, the tumors are too close to organs to be removed entirely. This is why patients need heated chemotherapy during the operation or another type of chemotherapy weeks later.
The patients either received HIPEC or dwell intraperitoneal chemotherapy weeks later as a second-line treatment. The three-year survival rate was nearly doubled in difference:
- 65.22% three-year survival for the HIPEC group
- 33.33% three-year survival for the systemic chemotherapy group
The reason HIPEC works so well is due to the direct access to the abdominal cavity. Surgeons and oncologists deliver the heated chemotherapy into the abdomen through catheters and wash the area in the tumor-killing toxins.
Substituting it for follow-up treatment either allows recurrence or doesn’t provide the same access to the disease area.
Sources & Author
- Value of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy to treat malignant peritoneal mesothelioma. American Journal of Translational Research. Retrieved from: https://pubmed.ncbi.nlm.nih.gov/34650746/. Accessed: 10/18/2021.
Sources & Author